A5069403448- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- COVID-19 and healthcare impacts
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Biomedical Ethics and Regulation
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Global Cancer Incidence and Screening
- Nutrition, Genetics, and Disease
- Reproductive Biology and Fertility
- COVID-19 Impact on Reproduction
- Venous Thromboembolism Diagnosis and Management
- MRI in cancer diagnosis
- Surgical Simulation and Training
- PARP inhibition in cancer therapy
- Pelvic floor disorders treatments
- Inflammatory Biomarkers in Disease Prognosis
- Neuroendocrine Tumor Research Advances
- COVID-19 Clinical Research Studies
- Economic and Financial Impacts of Cancer
- Hospital Admissions and Outcomes
- Chromatin Remodeling and Cancer
- Sexual function and dysfunction studies
Legacy Health
2022
NYU Langone Health
2018-2021
SUNY Downstate Health Sciences University
2021
State University of New York
2021
Gynecologic Oncology Group
2018-2020
Hinge Health
2020
New York University
2018-2019
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2018
University of Chicago
2015-2018
University of Illinois Chicago
2018
Previous studies examining communication of BRCA1/2 results with relatives and family uptake testing have sampled from predominantly white, high SES cohorts ascertained solely tertiary care centers. No focused on among diverse carriers. We conducted structured interviews 73 carriers identified at a public hospital cancer center. asked participants if each first- second-degree relative was aware their whether or not had tested. Generalized estimating equations rates predictors testing....
Background New York City (NYC) is the epicenter of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID‐19]) in United States. Clinical characteristics and outcomes vulnerable populations, such as those with gynecologic cancer who develop COVID‐19 infections, limited. Methods Patients from 6 NYC‐area hospital systems known a diagnosis were identified. Demographic clinical outcome data abstracted through review electronic medical records. Results Records for 121...
Background: Prior research suggests that women do not accurately estimate their risk for breast cancer. Estimating and informing of is essential tailoring appropriate screening reduction strategies. Methods: Data were collected BreastCARE, a randomized controlled trial designed to evaluate PC-tablet based intervention providing multiethnic primary care physicians with tailored information about cancer risk. We included ages 40–74 visiting general internal medicine clinics at one academic...
Individuals who carry deleterious BRCA mutations face significantly elevated risks of breast, ovarian, and other cancers. These individuals are also responsible for informing relatives their increased risk carrying the family mutation. Few interventions have been developed to facilitate this communication process.We Sharing Risk Information Tool (ShaRIT), a personalized educational intervention, support carriers as they discuss positive results implications with relatives. We conducted pilot...
To examine relationships among parity, mode of delivery, and other parturition-related factors with women's sexual function later in life.Self-administered questionnaires examined desire, activity, satisfaction, problems a multiethnic cohort women aged 40 years older at least one past childbirth event. Trained abstractors obtained information on from archived records. Multivariable regression models associations controlling for age, race or ethnicity, partner status, diabetes, general...
For women at potentially increased risk for ovarian cancer, data regarding screening and reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about non- carriers. We surveyed a large cohort after testing to identify prevalence posttest predictors risk-reducing interventions.A median 3.7 years testing, 1447 who received genetic counseling 2 hospital sites were surveyed, with 77.6% response rate. analyzed from 1077 survey...
Medical marijuana (MM) use is common among cancer patients, but relatively little known about the usage patterns and efficacy of MM used by gynecologic patients.Demographic clinical data were collected for patients prescribed between May 2016 February 2019. The electronic medical record was to query formulation prescribed, patterns, length use, symptom relief, side effect profile. Descriptive statistics calculated.Of 45 MM, 89% receiving chemotherapy; 56% undergoing primary treatment. a...
This study aims to determine the rate of postoperative venous thromboembolism (VTE) in endometrial cancer patients undergoing robotic hysterectomy with or without extended pharmacologic VTE prophylaxis.A retrospective chart review women other procedures for from January 2010 February 2015 was conducted at 2 institutions. Charts were manually abstracted, and rates within 30 60 days after surgery determined. Patients then stratified by those who did not receive total 403 included, which 367...
Highlights•Ferritin, procalcitonin, and CRP may have prognostic value for severe COVID-19 infection in gynecologic cancer patients.•Elevated admission white blood cell count, lactate, creatinine also be of disease.•D-dimer levels do not appear to predictive patients with cancer.AbstractObjectiveElevated inflammatory markers are severity mortality. It is unclear if these associated due underlying tumor related inflammation. We sought further understand the response cancer.MethodsPatients a...
Mounting evidence suggests disproportionate coronavirus disease 2019 (COVID-19) hospitalizations and deaths because of racial disparities. The association race in a cohort gynecologic oncology patients with severe acute respiratory syndrome-coronavirus 2 infection is unknown. Data were abstracted from COVID-19 among 8 New York City area hospital systems. A multivariable mixed-effects logistic regression model accounting for county clustering was used to analyze COVID-19-related...
•Cutaneous metastases in cervical cancer are rare and associated with a poor prognosis.•Treatment is typically palliative, utilizing chemotherapy radiation.•We report case of PD-L1 positive cutaneous that developed after initial recurrence.•For patients on checkpoint inhibitor therapy who develop skin toxicity, it important to rule out metastases.
Outcomes after genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome have not been well studied in underserved populations. We surveyed 1,123 BRCA testers from a counseling program serving an academic center (n=1,045) public county hospital (n=78) median of 3.7 years mutations BRCA1 BRCA2 (breast susceptibility genes). compared outcomes, screening rates, self-reported general health. found no differences outcomes between hospitals. Breast rates were similarly high at both...
We describe a case of the first successful treatment platinum refractory clear cell ovarian cancer with secondary cytoreductive surgery and placement Calypso transponders to facilitate post-operative volumetric arc radiation therapy. In setting both primary recurrent disease, patients are less responsive standard chemotherapy those treated therapy may have improved outcomes compared use other modalities. Volumetric implantable is feasible, allows for targeted sites metastatic disease while...
Abstract Background: Underserved families at risk of Hereditary Breast and Ovarian Cancer (HBOC) have decreased access to genetic cancer assessment (GCRA). Neither the process nor outcomes GCRA been carefully studied in large diverse underserved populations. The Consortium BRCA testers (CUB), formed 2010 among three county hospitals, aims rigorously study patient each site. Methods: CUB's founding members are: San Francisco General Hospital (SF), Stroger Cook County (Chicago), Grady Memorial...
5521 Background: Prior studies demonstrate the clonal heterogeneity of ovarian tumors but do not address relationship between genomic alteration profiles and treatment selection. We analyzed comprehensive profiling (CGP) results from paired recurrent OC tumor samples to identify changes in somatic mutations over time. Methods: DNA two or more FFPE collected serially during course clinical care 49 patients Clearity Foundation Data Repository was for (Mut), microsatellite instability (MSI),...
5564 Background: The NCCN recommends risk-reducing salpingo-oophorectomy (RRSO) for women with BRCA mutations by age 35-40 or upon completion of childbearing. We previously reported that RRSO was being performed at 43-44; and 46-47 when fertility considerations were excluded. Since these ages are past the guidelines, our objective to elucidate timing between genetic testing (GT) surgery (RRS) reasons delay. Methods: conducted a retrospective chart review identify who underwent 2012-2017....